Chelsie Petrie
Family · Oklahoma City, OKNPI 1083385934
Payments from drug & device makers
What this record shows
31 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 53.6% of the total. 2025 is the largest year on record at $5,697, more than ten times the $8 reported in 2021. Among family clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $41.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$4K
- Corcept Therapeutics$372
- Lilly USA, LLC$307
- Amgen$304
- Xeris Pharmaceuticals, Inc.$283
- Sanofi-aventis U.S. LLC$261
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$3,90052%
- Food & beverage$3,64348%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 16 | $4,047 |
| Corcept Therapeutics | 17 | $372 |
| Lilly USA, LLC | 15 | $307 |
| Amgen | 17 | $304 |
| Xeris Pharmaceuticals, Inc. | 15 | $283 |
| Sanofi-aventis U.S. LLC | 13 | $261 |
| Dexcom, Inc. | 15 | $260 |
| Novo Nordisk | 11 | $250 |
| Madrigal Pharmaceuticals | 8 | $246 |
| BETA Bionics, Inc. | 10 | $217 |
| Medtronic | 6 | $124 |
| Bayer | 5 | $85 |
| Cequr Corporation | 2 | $76 |
| Sequel Med Tech, LLC | 3 | $74 |
| AstraZeneca | 4 | $71 |
| Recordati_rare_diseases_inc. | 3 | $71 |
| Boehringer Ingelheim | 3 | $70 |
| Mannkind Corporation | 3 | $69 |
| Chiesi USA, Inc. | 3 | $66 |
| AbbVie | 3 | $55 |
| Hologic Sales And Service, LLC | 1 | $38 |
| Amneal Pharmaceuticals LLC | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $22 |
| Novartis | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $21 |
| GSK | 1 | $21 |
| Insulet Corporation | 1 | $20 |
| Abbott | 1 | $19 |
| Pfizer | 1 | $16 |
| Genentech USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,543 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $70,947 |
| OzempicSemaglutide | 26 | $44,150 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $39,489 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $29,952 |
| TrulicityDulaglutide | 21 | $24,543 |
| JardianceEmpagliflozin | 20 | $22,365 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 15 | $17,796 |
| Novolog FlexpenInsulin Aspart | 15 | $4,247 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $3,040 |
| Metformin Hcl ErMetformin Hcl | 15 | $119 |
| Levothyroxine Sodium | 17 | $68 |
| Glimepiride | 13 | $52 |
| Metformin Hcl | 13 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $307 | $95,49068 claims |
| Novo NordiskOzempic | $250 | $44,15026 claims |
| Boehringer IngelheimJardiance | $70 | $22,36520 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $6817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.